Sutton Wealth Advisors’s BioMarin Pharmaceuticals BMRN Stock Holding History

Sutton Wealth Advisors’s Portfolio BMRN Stock Details BMRN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2022 Q2	–	Sell	-15	Closed	-$1.16K	–	1644
2022 Q1	$1.16K	Hold	15	–	–	﹤0.01%	1304
2021 Q4	$1.32K	Buy	+15	New	+$1.24K	﹤0.01%	1262
2020 Q2	–	Sell	-82	Closed	-$6.93K	–	1213
2020 Q1	$6.93K	Hold	82	–	–	﹤0.01%	755
2019 Q4	$6.93K	Sell	82 -9	-10%	-$680	﹤0.01%	892
2019 Q3	$6.13K	Sell	91 -3	-3%	-$231	﹤0.01%	904
2019 Q2	$8.05K	Sell	94 -3	-3%	-$257	﹤0.01%	828
2019 Q1	$8.62K	Buy	97 +9	+10%	+$834	0.01%	820
2018 Q4	$7.49K	Buy	88 +82	+1,367%	+$7.8K	﹤0.01%	804
2018 Q3	$582	Sell	6 -251	-98%	-$25.1K	﹤0.01%	1076
2018 Q2	$24.2K	Hold	257	–	–	0.02%	526
2018 Q1	$20.8K	Hold	257	–	–	0.01%	554
2017 Q4	$22.9K	Hold	257	–	–	0.02%	510
2017 Q3	$23.9K	Hold	257	–	–	0.02%	483
2017 Q2	$23.3K	Hold	257	–	–	0.02%	468
2017 Q1	$22.6K	Hold	257	–	–	0.02%	473
2016 Q4	$21.3K	Buy	257 +3	+1%	+$258	0.02%	471
2016 Q3	$23.5K	Hold	254	–	–	0.02%	423
2016 Q2	$19.8K	Hold	254	–	–	0.02%	451
2016 Q1	$20.9K	Buy	+254	New	+$20.7K	0.02%	424

Other funds holding BMRN

Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Viking Global Investors Stamford, Connecticut $35.7B AUM 21.3% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Sutton Wealth Advisors's BMRN Position: Q2 2022 in Review

Sutton Wealth Advisors sold out of BioMarin Pharmaceuticals (BMRN) in Q2 2022, closing a stake of 15 shares — an estimated $1.16K sold.

Sutton Wealth Advisors first reported a position in BMRN in Q1 2016 and held it in 19 quarters. The position peaked at $24.2K in Q2 2018. 542 funds tracked by Wall St. Rank hold BMRN as of Q2 2022.

Sutton Wealth Advisors reported no remaining BioMarin Pharmaceuticals position as of Q2 2022 after selling out during the quarter.
Sutton Wealth Advisors sold 15 BioMarin Pharmaceuticals shares in Q2 2022, an estimated $1.16K.
Sutton Wealth Advisors first reported a position in BioMarin Pharmaceuticals in Q1 2016 and held it in 19 quarters.
Sutton Wealth Advisors's BioMarin Pharmaceuticals position peaked at $24.2K in Q2 2018.
542 funds tracked by Wall St. Rank held BioMarin Pharmaceuticals as of Q2 2022.

Based on Sutton Wealth Advisors's 13F filing for Q2 2022, filed 7 Nov 2023.